JP2022513351A5 - - Google Patents
Info
- Publication number
- JP2022513351A5 JP2022513351A5 JP2021545283A JP2021545283A JP2022513351A5 JP 2022513351 A5 JP2022513351 A5 JP 2022513351A5 JP 2021545283 A JP2021545283 A JP 2021545283A JP 2021545283 A JP2021545283 A JP 2021545283A JP 2022513351 A5 JP2022513351 A5 JP 2022513351A5
- Authority
- JP
- Japan
- Prior art keywords
- liquid formulation
- formulation according
- buffered liquid
- subject
- hypoglycemia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024168092A JP2025000798A (ja) | 2018-10-15 | 2024-09-27 | 高インシュリン血症性低血糖症の治療のためのアベキシド |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862745915P | 2018-10-15 | 2018-10-15 | |
| US62/745,915 | 2018-10-15 | ||
| US201862746229P | 2018-10-16 | 2018-10-16 | |
| US62/746,229 | 2018-10-16 | ||
| US201962823493P | 2019-03-25 | 2019-03-25 | |
| US62/823,493 | 2019-03-25 | ||
| PCT/US2019/056278 WO2020081534A1 (en) | 2018-10-15 | 2019-10-15 | Avexitide for the treatment of hyperinsulinemic hypoglycemia |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024168092A Division JP2025000798A (ja) | 2018-10-15 | 2024-09-27 | 高インシュリン血症性低血糖症の治療のためのアベキシド |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022513351A JP2022513351A (ja) | 2022-02-07 |
| JP2022513351A5 true JP2022513351A5 (enExample) | 2022-10-21 |
Family
ID=70283142
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021545283A Pending JP2022513351A (ja) | 2018-10-15 | 2019-10-15 | 高インシュリン血症性低血糖症の治療のためのアベキシド |
| JP2024168092A Pending JP2025000798A (ja) | 2018-10-15 | 2024-09-27 | 高インシュリン血症性低血糖症の治療のためのアベキシド |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024168092A Pending JP2025000798A (ja) | 2018-10-15 | 2024-09-27 | 高インシュリン血症性低血糖症の治療のためのアベキシド |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20210338780A1 (enExample) |
| EP (2) | EP3867266A4 (enExample) |
| JP (2) | JP2022513351A (enExample) |
| CN (1) | CN112867730A (enExample) |
| AU (2) | AU2019359807B2 (enExample) |
| BR (1) | BR112021006968A2 (enExample) |
| CA (1) | CA3115527A1 (enExample) |
| CL (1) | CL2021000892A1 (enExample) |
| IL (2) | IL314504A (enExample) |
| WO (1) | WO2020081534A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3115527A1 (en) * | 2018-10-15 | 2020-04-23 | Eiger Biopharmaceuticals, Inc. | Avexitide for the treatment of hyperinsulinemic hypoglycemia |
| US20240307501A1 (en) | 2021-06-21 | 2024-09-19 | Eiger Biopharmaceuticals, Inc. | Treatment of congenital hyperinsulinism with avexitide |
| WO2024220962A1 (en) * | 2023-04-21 | 2024-10-24 | The Board Of Trustees Of The Leland Stanford Junior University | Glp-1r antagonism to improve nutrition following gastrointestinal surgery |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8076288B2 (en) * | 2004-02-11 | 2011-12-13 | Amylin Pharmaceuticals, Inc. | Hybrid polypeptides having glucose lowering activity |
| WO2013120022A2 (en) * | 2012-02-08 | 2013-08-15 | Seneb Biosciences, Inc. | Treatment of hypoglycemia |
| WO2015022420A1 (en) * | 2013-08-16 | 2015-02-19 | Medimmune Limited | Gip and glp-1 receptor dual-agonists for the treatment of diabetes |
| SMT202100668T1 (it) * | 2015-05-22 | 2022-01-10 | Univ Leland Stanford Junior | Trattamento dell'ipoglicemia post-bariatrica con antagonisti del glp-1 |
| US10653753B2 (en) * | 2016-03-04 | 2020-05-19 | Eiger Biopharmaceuticals, Inc. | Treatment of hyperinsulinemic hypoglycemia with exendin-4 derivatives |
| JP7584894B2 (ja) * | 2016-11-21 | 2024-11-18 | アイガー・バイオファーマシューティカルズ・インコーポレイテッド | エキセンディン（９－３９）の緩衝製剤 |
| CA3115527A1 (en) * | 2018-10-15 | 2020-04-23 | Eiger Biopharmaceuticals, Inc. | Avexitide for the treatment of hyperinsulinemic hypoglycemia |
-
2019
- 2019-10-15 CA CA3115527A patent/CA3115527A1/en active Pending
- 2019-10-15 US US17/285,039 patent/US20210338780A1/en active Pending
- 2019-10-15 WO PCT/US2019/056278 patent/WO2020081534A1/en not_active Ceased
- 2019-10-15 CN CN201980068180.8A patent/CN112867730A/zh active Pending
- 2019-10-15 IL IL314504A patent/IL314504A/en unknown
- 2019-10-15 EP EP19873113.5A patent/EP3867266A4/en not_active Withdrawn
- 2019-10-15 BR BR112021006968-2A patent/BR112021006968A2/pt unknown
- 2019-10-15 EP EP23151717.8A patent/EP4233842A3/en active Pending
- 2019-10-15 JP JP2021545283A patent/JP2022513351A/ja active Pending
- 2019-10-15 AU AU2019359807A patent/AU2019359807B2/en active Active
-
2021
- 2021-04-05 IL IL282059A patent/IL282059A/en unknown
- 2021-04-12 CL CL2021000892A patent/CL2021000892A1/es unknown
-
2024
- 2024-09-27 JP JP2024168092A patent/JP2025000798A/ja active Pending
-
2025
- 2025-07-23 AU AU2025208421A patent/AU2025208421A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Koliaki et al. | The role of bariatric surgery to treat diabetes: current challenges and perspectives | |
| Pories et al. | Etiology of type II diabetes mellitus: role of the foregut | |
| Cătoi et al. | Metabolic mechanisms in obesity and type 2 diabetes: insights from bariatric/metabolic surgery | |
| Sakai et al. | Efficacy and safety of the SGLT2 inhibitor luseogliflozin in Japanese patients with type 2 diabetes mellitus stratified according to baseline body mass index: pooled analysis of data from 52-week phase III trials | |
| Khaodhiar et al. | Treating diabetes and prediabetes by focusing on obesity management | |
| AU2025220813A1 (en) | Treatment of post-bariatric hypoglycemia with GLP-1 antagonists | |
| De Block et al. | Current concepts in gastric motility in diabetes mellitus | |
| JP7639156B2 (ja) | チルゼパチド治療方法 | |
| Cho et al. | The clinical and metabolic effects of intragastric balloon on morbid obesity and its related comorbidities | |
| EP4164592B1 (en) | Pharmaceutical compositions containing enterokine-releasing substances in multiple dosage forms in combination with gelling agents | |
| Hady et al. | The influence of laparoscopic adjustable gastric banding and laparoscopic sleeve gastrectomy on weight loss, plasma ghrelin, insulin, glucose and lipids | |
| Sheehan et al. | Pramlintide for post‐bariatric hypoglycaemia | |
| IL314504A (en) | Abexitide for the treatment of hyperinsulinemic hypoglycemia | |
| Eid | Obesity and type 2 diabetes mellitus in South Dakota: focused insight into prevalence, physiology and treatment. | |
| Garber | Anti-obesity pharmacotherapy and the potential for preventing progression from prediabetes to type 2 diabetes | |
| Aluri et al. | Glucocorticoids and cornstarch therapy for non–islet cell tumor hypoglycemia: a case report | |
| US20100104602A1 (en) | Neurotoxin therapy for postprandial hyperglycemia | |
| Liday | Overview of the guidelines and evidence for the pharmacologic management of type 2 diabetes mellitus | |
| Closa et al. | Effects of bariatric surgery on glucose control, weight reduction and disease remission among patients with type 2 diabetes mellitus; A systematic review and meta-analysis | |
| Kashyap | Medical Management of the Patient After Bariatric Surgery Reevaluating Diabetes | |
| Haider et al. | Postprandial hypoglycemia: complication of peptic ulcer surgery | |
| RU2834226C2 (ru) | Композиция glp-1 для лечения ожирения и регулирования веса | |
| JP2017122068A (ja) | 治療用組成物 | |
| Cohen et al. | Metabolic Surgery for Type 2 Diabetes Mellitus in Patients with BMI< 35 kg/m2 | |
| Finer | Obesity and Diabetes |